Mar 4, 2026 08:00AM
Mar 4, 2026 08:00AM
Feb 3, 2026 07:31AM
Feb 3, 2026 07:30AM
Oct 24, 2025 07:30AM
Oct 24, 2025 07:30AM
Sep 16, 2025 07:30AM Mira Pharma (MIRA) Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
Sep 16, 2025 07:30AM
Aug 19, 2025 08:30AM
Aug 19, 2025 08:30AM
Aug 12, 2025 08:32AM
Aug 12, 2025 08:30AM
Jul 30, 2025 07:30AM
Jul 30, 2025 07:30AM MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
Jul 29, 2025 07:31AM
Jul 29, 2025 07:30AM
May 6, 2025 08:02AM
May 6, 2025 08:00AM
Apr 23, 2025 08:04AM
Apr 23, 2025 08:00AM
Apr 16, 2025 08:03AM Mira Pharma (MIRA) Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
Apr 16, 2025 08:00AM
Apr 1, 2025 08:00AM
Mar 24, 2025 07:33AM
Mar 24, 2025 07:30AM
Mar 13, 2025 08:00AM
Mar 4, 2025 08:02AM
Mar 4, 2025 08:00AM MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Dec 19, 2024 09:02AM
Dec 19, 2024 09:00AM
Dec 10, 2024 08:34AM
Dec 10, 2024 08:30AM
Oct 28, 2024 07:41AM
Oct 28, 2024 07:30AM
Oct 21, 2024 07:47AM Mira Pharma (MIRA) Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Oct 21, 2024 07:30AM
Sep 27, 2024 07:32AM
Sep 27, 2024 07:30AM
Sep 18, 2024 07:05AM
Sep 18, 2024 07:00AM
Sep 11, 2024 07:33AM
Sep 11, 2024 07:30AM MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Aug 26, 2024 08:00AM
Aug 19, 2024 07:33AM
Aug 19, 2024 07:30AM
Aug 12, 2024 08:00AM
Jul 25, 2024 07:00AM
Jul 22, 2024 08:05AM
Jul 22, 2024 08:00AM MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
Jul 15, 2024 07:01AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All